RT Journal Article SR Electronic T1 Circulating CD34+ Progenitor Cells are Predictive of All-Cause and Cardiovascular Mortality and are Influenced by Physical Activity. JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.24.20139220 DO 10.1101/2020.06.24.20139220 A1 David Muggeridge A1 Jennifer Dodd A1 Mark D. Ross YR 2020 UL http://medrxiv.org/content/early/2020/06/25/2020.06.24.20139220.abstract AB Background Circulating progenitor cells (CPCs) play an important role in vascular repair and may influence cardiovascular (CV) health and longevity. Exercise is known to modulate these cells via mobilization from the bone marrow. The primary aims of this study were to evaluate the association of CPCs with mortality and explore the association between physical activity (PA) and CPCs.Design We studied 1,751 individuals from the Framingham Offspring cohort (66 ± 9 years [40-92 years], 54% female). CPCs (CD34+, CD34+CD133+, CD34+CD133+KDR+) were measured in participants using flow cytometry. Multivariable cox regression analyses were performed to investigate relationship of CPCs with future CV event, CV mortality and all-cause mortality. Multivariate regression analyses were performed to determine the relationship between self-reported PA and CPC counts.Results Following adjustment for standard risk factors, there was an inverse association between CD34+ CPCs and all-cause mortality (hazard ratio (HR) per unit increase in CD34+, 0.79; 95% CI 0.64 – 0.98, P=0.036). CD34+CD133+ CPCs were inversely associated with CV mortality (HR 0.63, 95% CI 0.44 – 0.91, P=0.013). Associations of CD34+ and CD34+CD133+ with mortality were strongest in participants with pre-existing CVD. PA was associated with CD34+ CPCs only in CVD participants. This relationship was maintained after adjustment for confounding variables.Conclusions Higher number of CD34+ and CD34+ CD133+ CPCs were inversely associated with all-cause and CV mortality. These associations were strongest in participants already diagnosed with CVD. PA is independently associated with CD34+ CPCs in individuals with CVD only, suggestive of greater benefit for this population group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Edinburgh Napier University′s Research Excellence Grant (M.R). D.M. is supported by the European Union′s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Edinburgh Napier University and Boston University Medical CentreAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article were provided by the National Heart, Lung and Blood Institute (NHLBI) under license / by permission. Data will be shared on request to the corresponding author with permission of the NHLBI.